PriceTargets.com logo

NovoCure - NVCR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $32.83
  • Forecasted Upside: 97.67%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$16.61 As of 06/23/2025 05:00 PM ET
▼ -0.08 (-0.48%)

This chart shows the closing price for NVCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NovoCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCR

Analyst Price Target is $32.83
▲ +97.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $32.83, with a high forecast of $40.00 and a low forecast of $27.00. The average price target represents a 97.67% upside from the last price of $16.61.

This chart shows the closing price for NVCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in NovoCure. This rating has held steady since August 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/23/2025Piper SandlerLower TargetOverweight ➝ Overweight$42.00 ➝ $34.00
4/16/2025WedbushLower TargetNeutral ➝ Neutral$29.00 ➝ $27.00
4/10/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$29.00 ➝ $28.00
1/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
1/13/2025WedbushReiterated RatingNeutral$29.00
12/13/2024Piper SandlerBoost TargetOverweight ➝ Overweight$28.00 ➝ $42.00
12/2/2024WedbushReiterated RatingNeutral$24.00 ➝ $29.00
12/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $38.00
12/2/2024Evercore ISIUpgradeIn-Line ➝ Outperform$18.00 ➝ $30.00
11/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/16/2024HC WainwrightUpgradeNeutral ➝ Buy$24.00 ➝ $30.00
10/1/2024Evercore ISILower TargetIn-Line ➝ In-Line$21.00 ➝ $18.00
7/26/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$42.00 ➝ $40.00
7/26/2024HC WainwrightBoost TargetNeutral ➝ Neutral$22.00 ➝ $24.00
7/25/2024WedbushReiterated RatingHold ➝ Outperform$24.00
7/2/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$14.50 ➝ $20.00
6/4/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.00
6/3/2024WedbushReiterated RatingHold ➝ Outperform$21.00 ➝ $24.00
5/2/2024WedbushReiterated RatingNeutral$21.00
5/2/2024HC WainwrightLower TargetNeutral ➝ Neutral$24.00 ➝ $22.00
4/10/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/3/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$49.00 ➝ $42.00
3/27/2024WedbushReiterated RatingNeutral$21.00
3/27/2024HC WainwrightBoost TargetNeutral ➝ Neutral$22.00 ➝ $24.00
3/19/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$15.00 ➝ $17.00
2/23/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$14.00 ➝ $15.00
2/22/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
1/8/2024WedbushReiterated RatingNeutral$21.00
8/29/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$102.00 ➝ $49.00
8/28/2023HC WainwrightDowngradeBuy ➝ Neutral$85.00 ➝ $25.00
8/8/2023Piper SandlerUpgradeNeutral ➝ Overweight$45.00
8/4/2023Leerink PartnrsReiterated RatingOutperform
8/4/2023Leerink PartnersInitiated CoverageOutperform$51.00
8/4/2023SVB SecuritiesInitiated CoverageOutperform$51.00
7/28/2023Wells Fargo & CompanyLower TargetOverweight$104.00 ➝ $102.00
6/7/2023Piper SandlerLower Target$67.00 ➝ $62.00
6/7/2023HC WainwrightLower Target$115.00 ➝ $85.00
6/6/2023WedbushUpgradeUnderperform ➝ Neutral$53.00 ➝ $46.00
5/16/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$70.00 ➝ $104.00
5/4/2023HC WainwrightLower Target$130.00 ➝ $115.00
3/17/2023JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$99.00 ➝ $50.00
2/23/2023HC WainwrightLower Target$135.00 ➝ $130.00
1/17/2023Piper SandlerBoost Target$70.00 ➝ $80.00
1/6/2023JPMorgan Chase & Co.Boost TargetNeutral$86.00 ➝ $99.00
1/6/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$89.00 ➝ $107.00
1/5/2023HC WainwrightBoost TargetBuy$100.00 ➝ $140.00
11/29/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$74.00 ➝ $89.00
10/28/2022Wells Fargo & CompanyBoost TargetEqual Weight$70.00 ➝ $74.00
10/28/2022Truist FinancialLower TargetBuy$105.00 ➝ $102.00
10/28/2022HC WainwrightLower TargetBuy$115.00 ➝ $100.00
10/24/2022Piper SandlerDowngradeOverweight ➝ Neutral$90.00 ➝ $70.00
7/28/2022Piper SandlerLower Target$100.00 ➝ $90.00
7/5/2022Evercore ISIDowngradeIn-Line ➝ Underperform$55.00
5/16/2022HC WainwrightInitiated CoverageBuy$115.00
5/13/2022Piper SandlerLower Target$125.00 ➝ $100.00
2/8/2022Loop CapitalInitiated CoverageBuy$200.00
2/2/2022OppenheimerUpgradeMarket Perform ➝ Outperform$98.00
1/20/2022Truist FinancialUpgradeHold ➝ Buy$125.00
1/11/2022Wells Fargo & CompanyLower TargetEqual Weight$105.00 ➝ $70.00
1/6/2022Piper SandlerLower TargetOverweight ➝ Overweight$180.00 ➝ $130.00
10/25/2021Piper SandlerLower TargetOverweight$235.00 ➝ $195.00
7/30/2021Wells Fargo & CompanyLower TargetEqual Weight$215.00 ➝ $180.00
7/30/2021MizuhoLower TargetNeutral$229.00 ➝ $200.00
7/29/2021Piper SandlerReiterated RatingOverweight$240.00 ➝ $235.00
7/9/2021Piper SandlerBoost TargetOverweight$235.00 ➝ $240.00
7/1/2021Northland SecuritiesInitiated CoverageBuy$250.00
7/1/2021MizuhoDowngradeBuy ➝ Neutral$229.00
4/20/2021WedbushReiterated RatingNeutral ➝ Underperform$159.00 ➝ $154.00
4/19/2021Truist FinancialBoost TargetHold$132.00 ➝ $142.00
4/14/2021Northland SecuritiesBoost TargetOutperform$200.00 ➝ $250.00
4/14/2021WedbushDowngradeNeutral ➝ Underperform$159.00 ➝ $154.00
4/14/2021MizuhoBoost TargetPositive ➝ Buy$175.00 ➝ $242.00
4/13/2021Wells Fargo & CompanyBoost TargetPositive ➝ Equal Weight$135.00 ➝ $215.00
3/1/2021MizuhoBoost TargetBuy$150.00 ➝ $175.00
1/29/2021Truist FinancialBoost Target$118.00 ➝ $132.00
1/25/2021Piper SandlerBoost TargetOverweight$140.00 ➝ $225.00
1/12/2021WedbushBoost Target$110.00 ➝ $159.00
10/30/2020MizuhoBoost TargetBuy$84.00 ➝ $150.00
10/29/2020Piper SandlerBoost TargetOverweight$125.00 ➝ $140.00
9/23/2020Northland SecuritiesInitiated CoverageOutperform
9/18/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$116.00
9/17/2020Piper SandlerBoost Target$89.00 ➝ $125.00
9/17/2020Truist FinancialDowngradeBuy ➝ Hold$108.00
8/3/2020SunTrust BanksReiterated RatingBuy
7/31/2020WedbushReiterated RatingNeutral
7/31/2020MizuhoBoost TargetBuy$82.00 ➝ $84.00
7/30/2020OppenheimerReiterated RatingHold
7/30/2020Piper SandlerBoost Target$85.00 ➝ $89.00
7/6/2020MizuhoReiterated RatingBuy$82.00
(Data available from 6/23/2020 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2024
  • 21 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
12/25/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2025
  • 17 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
3/25/2025
  • 17 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2025
  • 23 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/24/2025
  • 11 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2025

Current Sentiment

  • 11 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $16.61
Low: $16.19
High: $16.80

50 Day Range

MA: $17.54
Low: $15.58
High: $19.40

52 Week Range

Now: $16.61
Low: $14.17
High: $34.13

Volume

767,961 shs

Average Volume

1,181,481 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of NovoCure?

The following sell-side analysts have issued stock ratings on NovoCure in the last year: Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Wall Street Zen, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for NVCR.

What is the current price target for NovoCure?

0 Wall Street analysts have set twelve-month price targets for NovoCure in the last year. Their average twelve-month price target is $32.83, suggesting a possible upside of 97.7%. Wells Fargo & Company has the highest price target set, predicting NVCR will reach $40.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $27.00 for NovoCure in the next year.
View the latest price targets for NVCR.

What is the current consensus analyst rating for NovoCure?

NovoCure currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NVCR.

What other companies compete with NovoCure?

Other companies that are similar to NovoCure include Stevanato Group, Glaukos, iRhythm Technologies, Inari Medical and TransMedics Group. Learn More about companies similar to NovoCure.

How do I contact NovoCure's investor relations team?

NovoCure's physical mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider's listed phone number is 441534756700 and its investor relations email address is [email protected]. The official website for NovoCure is www.novocure.com. Learn More about contacing NovoCure investor relations.